Oscar Health, Inc. (OSCR) saw its stock price plunge 8.35% in the latest 24-hour period, as investors reacted to a reaffirmed Sell rating from Barclays. The significant drop comes ahead of the next trading session, reflecting growing investor concerns about the health insurance technology company's prospects.

Barclays analyst Andrew Mok CFA maintained a Sell rating on Oscar Health, with a price target of $13.00. This bearish stance from a major financial institution appears to have sparked a sell-off among investors, contributing to the sharp decline in OSCR's stock price.

The reaffirmation of the Sell rating suggests that Barclays continues to have a negative outlook on Oscar Health's future performance. Investors will likely be watching closely for any additional analyst reports or company announcements in the coming days, as they seek to understand the full implications of this rating on Oscar Health's business model and growth prospects.